Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Colorcon
Harvard Business School
AstraZeneca

Last Updated: August 13, 2022

Details for Patent: 6,872,728


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,872,728
Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Abstract:GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR1## wherein A, Q, R.sub.1, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, R.sub.5, R.sub.6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s): Zhu; Yun-Fei (San Diego, CA), Chen; Chen (San Diego, CA), Tucci; Fabio C. (San Diego, CA), Guo; Zhiqiang (San Diego, CA), Gross; Timothy D. (San Diego, CA), Rowbottom; Martin (La Jolla, CA), Struthers; R. Scott (Encinitas, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:10/361,144
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 6,872,728

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
McKesson
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.